Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early stages of the disease. In recent years, the introduction of newer generation chemotherapy regimens in the adjuvant setting has improved the survival of patients treated with upfront resection. However, there a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Control 2023-01, Vol.30, p.10732748231173212
Main Authors: de Jesus, Victor Hugo Fonseca, Riechelmann, Rachel P.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - surgery
Chemotherapy
Hope In Despair - New Progress in The Diagnosis and Treatment of Pancreatic Cancer:Review
Humans
Neoadjuvant Therapy
Oncologists
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - surgery
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early stages of the disease. In recent years, the introduction of newer generation chemotherapy regimens in the adjuvant setting has improved the survival of patients treated with upfront resection. However, there are multiple theoretical advantages to deliver early systemic therapy in patients with localized pancreatic cancer. So far, the evidence supports the use of neoadjuvant therapy for patients with borderline resectable pancreatic cancer. The benefit of this treatment sequence for patients with resectable disease remains elusive. In this review, we summarize the data on adjuvant therapy for pancreatic cancer and describe which evidence backs the use of neoadjuvant therapy. Additionally, we address important issues faced in clinical practice when treating patients with localized pancreatic cancer.
ISSN:1073-2748
1526-2359
1526-2359
DOI:10.1177/10732748231173212